Dr. Shah on Toxicites Associated With CAR T-Cell Therapy
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.
Although the toxicities associated with with CAR T-cell therapy receive a lot of attention, it remains the most promising therapy for relapsed leukemia, says Shah.
Shah adds that is important to understand that these toxicities are manageable, and the risk of dying from them is extremely low.
Related Videos
Related Content
